BioVascular Inc. is a clinical stage privately held biotechnology company developing “first in class” products for platelet mediated cardiovascular diseases.

BioVascular’s initial product, saratin, is a polypeptide produced by recombinant means in yeast. This product was discovered by and licensed from Merck KGaA. BioVascular is conducting human clinical trials of saratin for use in hemodialysis access graft and peripheral artery grafts to reduce intimal hyperplasia, which can lead to failure of the graft.

BioVascular’s other product lowers platelet counts to potentially reduce mortality and morbidity rates in patients who have had a myocardial infarction, stroke or peripheral arterial disease.

Additionally the product, in a different dose form, can be used by patients with essential Thrombocythemia, a disease characterized by persistently high platelet counts, to improve dosing and tolerability.